Evidence Review
Stress-Related Fatigue (RCT, 2009)
The most methodologically rigorous trial was conducted by Olsson et al. (2009), a Phase III randomized, double-blind, placebo-controlled, parallel-group study enrolling 60 adults (ages 20–55) diagnosed with stress-related fatigue syndrome using Swedish National Board of Health criteria. Participants received 576 mg/day of SHR-5 extract or placebo for 28 days [1].
The rhodiola group showed statistically significant improvement on the Pines Burnout Scale (p = 0.047) and a trend toward improved scores on a saliva cortisol awakening response. Attention and concentration tasks also improved in the treatment group. The study used a stringent diagnostic entry threshold, making these results particularly relevant to people experiencing genuine burnout rather than ordinary tiredness.
Acute Mental Performance in Cadets (RCT, 2003)
Shevtsov et al. (2003) conducted a randomized, double-blind, placebo-controlled study with 161 military cadets aged 19–21 undergoing sleep deprivation and examination stress [2]. Subjects received a single dose of SHR-5 at one of two dose levels (2 or 3 capsules) or placebo, then completed a battery of mental performance and proofreading tests.
Both rhodiola doses produced a statistically significant antifatigue effect compared to placebo (p < 0.001), measured by an antifatigue index (AFI). The verum groups achieved AFI values of 1.039 and 1.020 for the two doses, versus 0.905 in the placebo group. No significant difference was found between the two active doses, suggesting a ceiling effect at lower doses in acute settings.
Physicians During Night Duty (Crossover RCT, 2000)
Darbinyan et al. (2000) tested a repeated low-dose regimen of SHR-5 in 56 young physicians during night shifts — a demanding real-world stress context [3]. The randomized, double-blind, crossover design allowed each participant to act as their own control. Physicians on rhodiola showed a statistically significant improvement in the Fatigue Index compared to placebo, and mental performance (speed and accuracy on neuromotor tests) improved during the treatment period and returned toward baseline during the washout phase, confirming the effect was drug-mediated.
Systematic Review (2012)
Ishaque et al. (2012) systematically reviewed 11 trials (10 RCTs, 1 controlled clinical trial) examining rhodiola for physical and mental fatigue [4]. Six trials investigated physical performance, four addressed mental performance, and two examined mental health conditions. The reviewers concluded that rhodiola showed promising effects across these domains but noted methodological heterogeneity — different extract preparations, doses, outcome measures, and populations — limiting definitive conclusions. Independent replication with standardized protocols was identified as the primary gap.
Anxiety and Mood (RCT, 2015)
Cropley et al. (2015) randomized 80 mildly anxious adults to rhodiola (2 × 200 mg/day of Vitano extract) or a no-treatment control for 14 days [5]. The rhodiola group showed significant reductions in self-reported anxiety, stress, anger, confusion, and depression, along with improvement in total mood. Notably, objective cognitive performance measures did not differ significantly between groups, suggesting rhodiola's primary benefit at this dose is emotional regulation rather than raw cognitive speed.
Evidence Synthesis (2022)
A comprehensive 2022 review by Stojcheva and Quintela evaluated the breadth of clinical evidence, finding consistent support for rhodiola's role in managing cognitive fatigue, burnout, and stress-related exhaustion [6]. The authors noted that the European Medicines Agency (EMA) has recognized rhodiola as a traditional herbal medicine for temporary relief of stress symptoms and fatigue — a regulatory acknowledgment that reflects the accumulated clinical record.
Strength of Evidence
The evidence for rhodiola's antifatigue and anti-burnout effects in humans is moderate-to-good by herbal supplement standards: multiple RCTs, a systematic review, and regulatory recognition, with consistent direction of effect. The main limitations are relatively small sample sizes, short durations (most trials under 12 weeks), and variation in extract preparations. Rhodiola is not a substitute for addressing the sources of chronic stress, but as an adjunctive tool it has a substantially better evidence base than most adaptogens.